EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacological prevention in cardio-oncology: from bench-to-bedside

Ashot A Avagimyan, Nana Pogosova, Federica Fogacci, Olga Urazova, Zinaida Djndoyan, Liliya Mirzoyan, Gayane Avetisyan, Marco Bernardi, Luigi Spadafora, Davood Shafie, Francesco Perone, Marzieh Taheri und 6 weitere

Heart Failure Reviews · 02.12.2025 · 31 (1)

DOI: 10.1007/s10741-025-10575-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 02.12.2025. Verfasst von Ashot A Avagimyan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Diseases Propedeutics, Yerevan State Medical University, Yerevan, 0025, Armenia. ashot.avagimyan@meduni.am. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advancements in oncology have markedly enhanced cancer survival rates; however, anticancer therapies, particularly anthracyclines, pose significant cardiovascular (CV) risks, collectively referred to as cancer therapy-related cardiovascular toxicity (CTR-CVT). This review consolidates evidence on strategies to mitigate CTR-CVT especially associated with anthracyclines. Neurohormonal blockers, including ACE inhibitors, ARBs, and β-blockers, constitute the foundation of prevention, although their efficacy varies: combinations such as ACEi/ARB with βB yield mixed outcomes, whereas carvedilol offers antioxidant benefits beyond β-blockade. Sacubitril/valsartan (ARNI) has demonstrated improvements in global longitudinal strain and LVEF preservation in the SARAH trial, albeit with associated hypotension risks. Aldosterone antagonists show potential, with spironolactone preserving LVEF and diastolic function, though eplerenone has not shown significant effects. Statins present conflicting data; the STOP-CA trial supports atorvastatin for LVEF preservation, while the PREVENT and SPARE-HF trials found no benefit. Emerging evidence suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin and empagliflozin, as promising agents, with preclinical and early clinical data indicating cardioprotection through metabolic modulation, anti-inflammatory effects, and reduced oxidative stress. Gaps remain in understanding CTR-CVT pathophysiology, risk stratification, and the translation of preclinical findings. Future efforts should prioritize personalized approaches, dynamic risk assessment (e.g., HFA-ICOS tool), and a paradigm shift from oxidative stress to cardiometabolic dysfunction. Multidisciplinary collaboration is essential to optimize oncological outcomes while minimizing CV toxicity, with SGLT2i representing a key frontier for validation in ongoing trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsCardiovascular DiseasesHumansCardiotoxicityCardio-Oncology

Stichwörter der Autor:innen

Cardio-oncologyCardiotoxicityDoxorubicinPrevention

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Diseases Propedeutics, Yerevan State Medical University, Yerevan, 0025, Armenia. ashot.avagimyan@meduni.am.
  • Deputy Director of Research and Preventive Cardiology, National Medical Research Centre of Cardiology, Moscow, 121552, Russia.
  • Head of Evidence Based Medicine Department, Peoples' Friendship University of Russia, Moscow, 117198, Russia.
  • Hypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, University of Bologna, Bologna, 40138, Italy.
  • Head of Pathophysiology Department, Siberian State Medical University, Tomsk, 634050, Russia.
  • Department of Internal Diseases Propedeutics, Yerevan State Medical University, Yerevan, 0025, Armenia.

Zitieren

APA

Avagimyan, A. A., Pogosova, N., Fogacci, F., Urazova, O., Djndoyan, Z., Mirzoyan, L., Avetisyan, G., Bernardi, M., Spadafora, L., Shafie, D., Perone, F., Taheri, M., Cicero, A., Zoccai, G. B., Asteggiano, R., Madonna, R., De Caterina, R., & Sarrafzadegan, N. (2025). Pharmacological prevention in cardio-oncology: from bench-to-bedside. Heart Failure Reviews, 31(1). https://doi.org/10.1007/s10741-025-10575-2

Vancouver

Avagimyan AA, Pogosova N, Fogacci F, Urazova O, Djndoyan Z, Mirzoyan L, et al. Pharmacological prevention in cardio-oncology: from bench-to-bedside. Heart Failure Reviews. 2025;31(1). doi:10.1007/s10741-025-10575-2

BibTeX
@article{Avagimyan2025,
  author = {Avagimyan, Ashot A and Pogosova, Nana and Fogacci, Federica and Urazova, Olga and Djndoyan, Zinaida and Mirzoyan, Liliya and Avetisyan, Gayane and Bernardi, Marco and Spadafora, Luigi and Shafie, Davood and Perone, Francesco and Taheri, Marzieh and Cicero, Arrigo and Zoccai, Giuseppe Biondi and Asteggiano, Riccardo and Madonna, Rosalinda and De Caterina, Raffaele and Sarrafzadegan, Nizal},
  title = {Pharmacological prevention in cardio-oncology: from bench-to-bedside},
  journal = {Heart Failure Reviews},
  year = {2025},
  volume = {31},
  number = {1},
  doi = {10.1007/s10741-025-10575-2}
}
Kostenlos starten →